Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.09T
24h Vol:
$8.59B
Dominance:
MSFT:4.90%
Stocklytics Platform
Asset logo for symbol TECH
Bio-Techne
TECH
58
$75.87arrow_drop_down1.31%-$1.00
S&P500

Performance History

Chart placeholder
Key Stats
Open$76.50
Prev. Close$76.88
EPS1.25
Dividend$0.32
Next Earnings DateAug 20, 2024
Dividend Yield %0.42%
Market Cap$12.14B
PE Ratio60.70
LOWHIGH
Day Range74.79
77.02
52 Week Range51.79
89.91
Ratios
P/B Ratio5.34
Revenue$1.13B
Operating M. %23.74%
Earnings$285.44M
Earnings Growth %8.49%
EBITDA Margin %28.71%
ROE %10.40%
EPS1.25

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

info
There's no data available for Analyst Forecast

Analyst Ratings

info
There's no data available for Analyst Ratings

Correlated Companies

PRICE$878.45
24H (%)arrow_drop_down0.55%
24H ($)-$4.88
MARKET CAP$771.28B
PRICE$497.12
24H (%)arrow_drop_down0.03%
24H ($)-$0.17
MARKET CAP$443.63B
PRICE$145.53
24H (%)arrow_drop_up0.06%
24H ($)$0.09
MARKET CAP$347.62B
PRICE$129.48
24H (%)arrow_drop_up0.08%
24H ($)$0.11
MARKET CAP$318.88B

About Bio-Techne (TECH)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It has strategic partnership with Lunaphore Technologies S.A. to develop automated same-slide spatial multiomics solution. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Charles R. Kummeth
Headquarters
Minneapolis
Employees
3000
Exchange
NASDAQ
add Bio-Techne to watchlist

Keep an eye on Bio-Techne

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Bio-Techne's (TECH) price per share?

The current price per share for Bio-Techne (TECH) is $75.87. The stock has seen a price change of -$1.01 recently, indicating a -1.31% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Bio-Techne (TECH)?

For Bio-Techne (TECH), the 52-week high is $89.91, which is 18.51% from the current price. The 52-week low is $51.79, the current price is 46.5% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Bio-Techne (TECH) a growth stock?

Bio-Techne (TECH) has shown an average price growth of 0.41% over the past three years. It has received a score of 30 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Bio-Techne as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Bio-Techne (TECH) stock price performance year to date (YTD)?

As of the latest data, Bio-Techne (TECH) has a year-to-date price change of -1.1%. Over the past month, the stock has experienced a price change of -9.14%. Over the last three months, the change has been 4.62%. Over the past six months, the figure is -0.16%. Looking at a longer horizon, the five-year price change stands at 46.45%.

help
Is Bio-Techne (TECH) a profitable company?

Bio-Techne (TECH) has a net income of $285.44M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 67.72% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 23.74% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.14B, with a revenue growth rate of 2.81%, providing insight into the company's sales performance and growth. The gross profit is $769.82M. Operating income is noted at $298.94M. Furthermore, the EBITDA is $359.57M.

help
What is the market capitalization of Bio-Techne (TECH)?

Bio-Techne (TECH) has a market capitalization of $12.15B. The average daily trading volume is 822.17K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level